Yeni Kuşak Oral Antikoagülanlara Bağlı Kanamalarda Acil Servis Yönetimi

Ozlem Koksal; Vahide Aslıhan Durak

Derleme

BibTex

RIS

Kaynak Göster

Yıl 2020, Cilt: 3 Sayı: 2, 62 - 65, 30.06.2020

Ozlem Koksal , Vahide Aslıhan Durak

Öz

New generation oral anticoagulant (NOAC) drugs are widely used today, as they have more advantages in some clinical situations and they do not require close monitoring for their dosage.
Rarely, they increase the risk of bleeding like the other anticoagulant drugs and are not able to be monitored in the high dose intakes. Due to these reasons, the management of these patients in emergency department should be specific.
In this article, the emergency service management of patients with bleeding associated with the use of NOAC drugs will be discussed.

Anahtar Kelimeler

New generation oral anticoagulants, bleeding, management, emergency department

Kaynakça

Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with two doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation. 2011;123(21):2363-72.
Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361: 1139-1151.
Levine M, Goldstein JH. Bleeding complications of targeted oral anticoagulants. Hematology Am Soc Hematol Educ Program. 2014;1:504-509.
Levine M, Pizon AF, Padilla-Jones A, et al. Warfarin overdose: a 25 year experience. J Med Toxicol. 2014;10:156-164.
Pfeiffer H, Herbst L, Schwarze B, et al. Massive intoxication with rivaroxaban, phenprocoumon, and diclofenac: a case report. Medicine (Baltimore). 2016;95:e5343.
Repplinger DJ, Hoffman RS, Nelson LS, et al. Lack of significant bleeding despite large acute rivaroxaban overdose confirmed with whole blood concentrations. Clin Toxicol. 2016;54:647-649.
Lehmann T, Hofer KE, Baumann M, et al. Massive human rivaroxaban overdose. Thromb Haemost. 2014;112:834-836.
Sajkov D, Gallus A. Accidental rivaroxaban overdose in a patient with pulmonary embolism: some lessons for managing new oral anticoagulants. Clin Med Insights Case Rep. 2015;8:57-59.
Barton J, Wong A, Graudins A. Anti-X activity in apixaban overdose: a case report. Clin Toxicol (Phila). 2016;54:871-873.
Peetermans M, Pollack CJr, Reilly P, et al. Idarucizumab for dabigatran overdose. Clin Toxicol (Phila). 2016;54:644-646.
Shapiro S, Bhatnagar N, Khan A, et al. Idarucizumab for dabigatran overdose in a child. Br J Haematol. 2018;180(3):457-459. doi: 10.1111/bjh.14371.
Vlad I, Armstrong J, Ridgley J, et al. Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring. Clin Toxicol (Phila). 2016;54:286-289.
Mumoli N, Cei M, Fiorini M, et al. Conservative management of intentional massive dabigatran overdose. Blood Coagul Fibrinolysis. 2015;26:225-229.
Chiew AL, Khamoudes D, Chan BS, et al. Use of continuous veno- venous haemodiafiltration therapy in dabigatran overdose. Clin Toxicol (Phila). 2014;52:283-287.
Woo JS, Kapadia N, Phanco SE, et al. Positive outcome after intentional overdose of dabigatran. J Med Toxicol. 2013;9:192-195.
Kocabay G, Okcular I, Akkaya V, et al. Suicide attempt with clopidogrel. Hum Exp Toxicol. 2006;25:731-734.
Michael Levine, Michael C. Beuhler, et al. Assessing Bleeding Risk in Patients With Intentional Overdoses of Novel Antiplatelet and Anticoagulant Medications. Annals of Emergency Medicine. 2018;71(3): 273-8.
Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Practice & Research Clinical Haematology. 2013; 26:191-202.
https://www.uptodate.com/contents/direct-oral-anticoagulants-and-parenteral-direct-thrombin-inhibitors-dosing-and-adverse-effects?search=new%20anticoagulants&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1
Goldfrank's Toxicologic Emergencies.pdf. 2015. Betty C Chen, Marc Su. Chapter 60: Antithrombotics, 1383-1395.
Harder S, Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013;69:1617-33.
Gomez-Outes A, Suarez-Gea ML, Lecumberri R et al. Direct-acting oral anticoagulants: pharmacology, indications, management, and future perspectives. Eur J Haematol. 2015;19:389-404. doi:10.1111/ejh.12610.
Liew A, Eikelboom JW, O’Donnel M, et al. Assesment of Anticoagulation Intensity and Management of Bleeding With Old and New Oral Anticoagulants. Canadian Journal of Cardiology 29 (2013) S34eS44
Warkentin TE, Greinacher A, Koster A. Bivalirudin. ThrombHaemost 2008; 99:830.
Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20:318.
Graetz TJ, Tellor BR, Smith JR, et al. Desirudin: a review of the pharmacology and clinical application for the prevention of deep vein thrombosis. ExpertRevCardiovascTher 2011; 9:1101.
https://www.uptodate.com/contents/risks-and-prevention-of-bleeding-with-oral-anticoagulants?search=edoxaban&topicRef=1370&source=see_link
Protrombin Kompleks Konsantresi (PCC), Editör: Y.Çete, Medical Network. S:45-58.
Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019 Jun;94(6):697-709. doi: 10.1002/ajh.25475
Vlad I, Armstrong J, Ridgley J, et al. Dabigatran deliberate overdose: two cases and suggestions for laboratory monitoring. Clinical Toxicolog, 2016 Vol. 54, No. 3, 286–289. doi.org/10.3109/15563650.2015.1126287